Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
FagronARSUF +1.85%90 5-Year Yield-on-Cost % is 0.00 as of Aug. 14, 2026. GuruFocus rates ARSUF with a GF Score™ of 90/100 and a GF Value™ of $30.08 (Fairly Valued). The stock has 2 warning signs investors should review. Among 511 Drug Manufacturers companies, Fagron ranks better than 80.43% on this metric.
Fagron's yield on cost for the quarter that ended in Jun. 2026 was 0.00.
The historical rank and industry rank for Fagron's 5-Year Yield-on-Cost % or its related term are showing as below:
During the past 13 years, Fagron's highest Yield on Cost was 47.12. The lowest was 1.40. And the median was 4.50.
ARSUF's 5-Year Yield-on-Cost % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.28 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Fagron 5-Year Yield-on-Cost % Related Terms
ARSUF vs ZTS, UTHR, VTRS: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Fagron's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fagron 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Fagron's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Fagron's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of Fagron is calculated as
Fagron (ARSUF) has a 5-Year Yield-on-Cost % of 0.00 as of Aug. 14, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Fagron and its competitors. Over the past decade, Fagron's 5-Year Yield-on-Cost % has ranged from 1.40 to 47.12. According to the industry distribution chart, Fagron ranks #100 out of 511 companies in the Drug Manufacturers industry, placing it in the top 19.6%.
Is Fagron's 5-Year Yield-on-Cost % too high?
Fagron's current 5-Year Yield-on-Cost % is 0.00. Over the past 10 years, this metric has ranged from a low of 1.40 to a high of 47.12. Based on the distribution chart, Fagron ranks #100 out of 511 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Fagron has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Fagron's 5-Year Yield-on-Cost % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Fagron ranks #100 out of 511 companies for 5-Year Yield-on-Cost %. This places Fagron in the top 20% of its industry — outperforming the majority of peers. The industry median 5-Year Yield-on-Cost % is 2.28. Historically, Fagron's own 5-Year Yield-on-Cost % has ranged from 1.40 to 47.12 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.28, based on 511 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Fagron and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fagron's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fagron stock overvalued right now?
Based on GuruFocus' analysis, Fagron (ARSUF) is currently considered Fairly Valued. The stock's GF Value™ is $30.08, compared to a current price of $27.50 — trading 8.6% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. Fagron's overall GF Score™ is 90/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Fagron (ARSUF), the current 5-Year Yield-on-Cost % is 0.00 as of Aug. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fagron (ARSUF) Overvalued in 2026?
Based on GuruFocus' analysis, Fagron stock appears to be undervalued.
The current stock price of $27.50 is trading 8.6% below its estimated GF Value™ of $30.08.
GuruFocus considers Fagron to be Fairly Valued.
Key valuation signals for ARSUF:
5-Year Yield-on-Cost %: 0.00
GF Value™: $30.08 vs. price of $27.50 (8.6% below fair value)
No single metric tells the full story. See the ARSUF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fagron SA is a Belgium-based multinational pharmaceutical compounding company specializing in pharmaceutical compounding. It operates across the pharmaceutical compounding value chain, developing and manufacturing personalized medicines in collaboration with pharmacists, prescribers, hospitals, and other healthcare providers. The company has three segments: Essentials, Brands, and Compounding Services. The majority of the revenue is derived from the Essentials segment, which provides raw materials, equipment, packaging, and supplies for compounding to pharmacies and healthcare industries across EMEA, Latin America, and North America - Pacific. Geographically, it generates the maximum revenue from Fagron North America - Pacific.
90GF Score
Get the complete analysis for ARSUF
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ARSUF has been successfully added to your 
